<DOC>
	<DOCNO>NCT01202227</DOCNO>
	<brief_summary>The purpose study assess safety long-term use pregabalin dose 600 mg/day patient central neuropathic pain ( post spinal cord injury pain , post stroke pain , multiple sclerosis pain ) .</brief_summary>
	<brief_title>An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Spinal Cord Diseases</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Inclusion criterion subject shift Study A0081107 Subjects complete 18week study period Study A0081107 conduct chronic neuropathic pain spinal cord injury ; Subjects complete assessment efficacy endpoint end treatment phase precede Study A0081107 ( V7 ) ; Inclusion criterion subject new participant study Subjects central neuropathic pain stroke multiple sclerosis ; At least 6 month pass onset central neuropathic pain ; Pain VAS least 40mm Visit 1 Visit 2 ; Creatinine clearance &lt; 60 mL/min ; Platelet count &lt; 100 Ã— 103/mm3 ; White blood cell ( WBC ) count &lt; 2500 / mm3 ; Neutrophil count &lt; 1500/ mm3 ; Subjects expect require surgery trial ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Wounds Injuries</keyword>
	<keyword>Trauma</keyword>
	<keyword>Nervous System</keyword>
	<keyword>pregabalin</keyword>
</DOC>